🇺🇸·18h agoIndustry
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
Publisher
U
United Therapeutics (IR)
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- United Therapeutics (IR)
- Region
- USA
- Scope
- Industry
- Published
- July 29, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on ir.unither.com
Leave the platform to read the original full article on the publisher site.
Source: United Therapeutics (IR)
Scope: Industry
Related coverage
More related coverage
Allogene Therapeutics/6h ago
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Merck & Co. (MSD) News/3h ago
Merck Announces Fourth-Quarter 2026 Dividend
GSK News/9h ago
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
Chugai Pharmaceutical News/10h ago